SCHEMBL2032409

SCHEMBL2032409

N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC(c2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 4/20 0.60
DPP4 P27487 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
MPO P05164 1/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
BLM P54132 1/20 0.59
PMP22 Q01453 1/20 0.59
HIF1A Q16665 1/20 0.59
DRD2 P14416 1/20 0.58
DRD4 P21917 1/20 0.58
DRD3 P35462 1/20 0.58
MMP3 P08254 1/20 0.55
SOS1 Q07889 5/20 0.54
KRAS P01116 1/20 0.54
ARG1 P05089 1/20 0.52
AKT1 P31749 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032411 1.00 SMYD3 (0.60) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL8689594 0.84 DPP4 (0.56) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL8689586 0.84 DPP4 (0.56) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL15084031 0.84 MMP3 (0.59) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL9452845 0.84 KMT2A (0.64) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL7420410 0.84 DPP4 (0.58) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL27633966 0.83 MEN1 (0.62) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL3788185 0.82 MEN1 (0.61) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL3788187 0.82 MEN1 (0.61) SMYD3DPP4MEN1KMT2AKDM4E
SCHEMBL15081812 0.82 MMP3 (0.56) SMYD3MEN1KMT2ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883721-B2 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof MCGILL UNIVERSITY (CA) 2014-11-11 US claimed
US-20120135918-A1 METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF MCGILL UNIVERSITY (CA) 2012-05-31 US claimed
US-20090069245-A1 GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2009-03-12 US claimed
US-10550377-B2 Suppression of prostate cancer using a targeted clostridial neurotoxin IPSEN BIOINNOVATION LIMITED (GB) 2020-02-04 US disclosed
EP-2719392-B1 Fusion proteins for use in the treatment of acromegaly IPSEN BIOINNOVATION LTD (GB) 2019-07-24 EP disclosed
US-20190127718-A1 SUPPRESSION OF CANCER IPSEN BIOINNOVATION LIMITED (GB) 2019-05-02 US disclosed
EP-3473643-A1 FUSION PROTEINS FOR USE IN THE TREATEMNT OF CANCER Ipsen Bioinnovation Limited (GB) 2019-04-24 EP disclosed
EP-2310029-B1 Fusion proteins for use in the treatment of cancer IPSEN BIOINNOVATION LTD (GB) 2019-04-03 EP disclosed
US-10240138-B2 Polypeptides that bind to and inhibit secretion from growth hormone secreting cells IPSEN BIOINNOVATION LIMITED 2019-03-26 US disclosed
US-10113159-B2 Suppression of cancer IPSEN BIOINNOVATION LIMITED (GB) 2018-10-30 US disclosed
EP-3241560-A1 SUPPRESSION OF CANCER Ipsen Bioinnovation Limited (GB) 2017-11-08 EP disclosed
EP-2364166-B1 SUPPRESSION OF CANCER SYNTAXIN LTD (GB) 2013-05-15 EP disclosed
US-20120135918-A1 METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF MCGILL UNIVERSITY (CA) 2012-05-31 US disclosed
US-20110171191-A1 SUPPRESSION OF NEUROENDOCRINE DISEASES SYNTAXIN LIMITED (GB) 2011-07-14 US disclosed
US-20110165137-A1 SUPPRESSION OF CANCERS SYNTAXIN LIMITED (GB) 2011-07-07 US disclosed
US-20110158973-A1 SUPPRESSION OF CANCERS SYNTAXIN LIMITED (GB) 2011-06-30 US disclosed
US-20110160135-A1 SUPPRESSION OF NEUROENDOCRINE DISEASES SYNTAXIN LIMITED (GB) 2011-06-30 US disclosed
WO-2010132580-A2 METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2010-11-18 WO disclosed
US-20090069245-A1 GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2009-03-12 US disclosed
WO-2007127457-A9 GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF UNIV TULANE (US) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135918-A1 METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF GHSR, GIPR, GHRHR SMYD3 3189/4885DPP4 394/4885MEN1 1896/4885
US-20090069245-A1 GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF GHSR, GHRHR, GIPR SMYD3 4418/4885DPP4 686/4885MEN1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.